Motive Capital Corp. (MOTV) Shareholders Approve Forge Global Deal
by Marlena Haddad on 2022-03-15 at 5:10pm

Motive Capital Corp. (NYSE:MOTV) announced this afternoon that its shareholders have voted to approve its combination with investment marketplace Forge Global, Inc.

Approximately 93.98% of the votes cast at today’s special meeting voted to approve the business combination with Forge.

The press release did not disclose much information on redemptions, but MOTV traded below its trust value of $10 throughout its redemption deadline March 11. Although the SPAC has struggled to break above the $10 mark since last April, it was able to reach a high of $10.30 yesterday.

Motive Capital financed the deal with $414 million from its current trust, a $50 million forward purchase agreement (FPA) and a $69 million PIPE at $10 per share. The PIPE was anchored by a $50 million commitment from the ION Group and contributions from Temasek and Adit Ventures.

The closing of the business combination is expected to take place next Monday, March 21. The combined company will be renamed Forge Global Holdings, Inc., and its common stock and warrants are expected to trade on the NYSE beginning on Tuesday, March 22, under the ticker symbols “FRGE” and “FRGE WS”, respectively.

The parties initially announced their $1.6 billion combination last year on September 13. San Francisco-based Forge provides a platform for users to invest in private companies via tender offers or regular cash-outs by employees and shareholders.


ADVISORS

  • Financial Technology Partners and FTP Securities (FT Partners) served as financial advisors to Forge.
  • JMP Securities LLC, Piper Sandler, Oppenheimer & Co. Inc., and William Blair & Company, LLC acted as capital markets advisors to Forge.
  • Goodwin Procter LLP acted as legal advisor to Forge.
  • UBS Investment Bank is serving as financial advisor to Motive Capital Corp.
  • Gibson, Dunn & Crutcher LLP acted as legal advisor and Oliver Wyman served as a strategic advisor to Motive Capital Corp.
  • UBS Investment Bank and J.P. Morgan are serving as capital markets advisors and placement agents to Motive Capital Corp.
  • Mayer Brown LLP acted as legal advisor to the placement agents.
Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved